Paclitaxel chemotherapy for the treatment of gastric cancer

被引：114
作者：
Sakamoto, Junichi [1 ]
Matsui, Takanori [3 ]
Kodera, Yasuhiro [2 ]
机构：
[1] Nagoya Univ, Grad Sch Med, Dept Young Leaders Program Med Adm, Showa Ku, Aichi 4668550, Japan
[2] Nagoya Univ, Grad Sch Med, Dept Digest Surg, Nagoya, Aichi 4648601, Japan
[3] Aichi Hosp, Aichi Canc Ctr, Dept Surg, Okazaki, Aichi, Japan
来源：
GASTRIC CANCER | 2009年 / 12卷 / 02期
关键词：
Paclitaxel; Gastric cancer; Chemotherapy; PHASE-II TRIAL; CISPLATIN COMBINATION CHEMOTHERAPY; CONTINUOUS-INFUSION; 5-FLUOROURACIL; LOW-DOSE PACLITAXEL; BIWEEKLY PACLITAXEL; CLINICAL-TRIAL; ADJUVANT CHEMORADIATION; PATHOLOGICAL RESPONSE; CONCURRENT RADIATION; PLUS PACLITAXEL;
D O I：
10.1007/s10120-009-0505-z
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A comprehensive review of phase I and phase II clinical trials of paclitaxel and paclitaxel-containing chemotherapy regimens for advanced gastric cancer was performed. Response rates, median progression-free survivals, and median overall survivals were examined, together with the treatment regimens and the numbers of patients registered in each trial. Although paclitaxel monotherapy produced considerable improvement in tumor response and prognosis, combination doublet or triplet chemotherapy with fluoropyrimidines and/or platinum compounds showed better results than the paclitaxel monotherapy. With regard to the schedule of paclitaxel administration, weekly injection seemed to show less toxicity and better results than administration every 3 weeks. Adjuvant therapies, chemoradiation therapies, and paclitaxel treatment for gastric ascites were also investigated and are discussed.
引用
收藏
页码：69 / 78
页数：10
相关论文
共 87 条
[1]  
Ajani JA, 1998, ONCOLOGY-NY, V12, P99
[2]   Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: Degree of pathologic response and not clinical parameters dictated patient outcome [J].
Ajani, JA ;
Mansfield, PF ;
Crane, CH ;
Wu, TT ;
Lunagomez, S ;
Lynch, PM ;
Janjan, N ;
Feig, B ;
Faust, J ;
Yao, JC ;
Nivers, R ;
Morris, J ;
Pisters, PW .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (06) :1237-1244
[3]  
Ajani JA, 1998, CANCER J SCI AM, V4, P269
[4]   Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): Quality of combined modality therapy and pathologic response [J].
Ajani, Jaffer A. ;
Winter, Kathryn ;
Okawara, Gordon S. ;
Donohue, John H. ;
Pisters, Peter W. T. ;
Crane, Christopher H. ;
Greskovich, John F. ;
Anne, P. Rani ;
Bradley, Jeffrey D. ;
Willett, Christopher ;
Rich, Tyvin A. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (24) :3953-3958
[5]   Doxifluridine combined with weekly paclitaxel for second-line treatment in patients with gastric cancer resistant to TS-1 [J].
Arai, Wataru ;
Hosoya, Yoshinori ;
Hyodo, Masanobu ;
Haruta, Hidenori ;
Kurashina, Kentaro ;
Saito, Shin ;
Hirashima, Yuuki ;
Yokoyama, Taku ;
Zuiki, Toru ;
Sakuma, Kazuya ;
Yasuda, Yoshikazu ;
Nagai, Hideo .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2007, 12 (02) :146-149
[6]  
Bokemeyer C, 1997, SEMIN ONCOL, V24, pS96
[7]  
BURKHART CA, 1994, CANCER RES, V54, P5779
[8]   Phase II study of paclitaxel in pretreated advanced gastric cancer [J].
Cascinu, S ;
Graziano, F ;
Cardarelli, N ;
Marcellini, M ;
Giordani, P ;
Menichetti, ET ;
Catalano, G .
ANTI-CANCER DRUGS, 1998, 9 (04) :307-310
[9]   Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum [J].
Chang, HM ;
Kim, TW ;
Ryu, BY ;
Choi, SJ ;
Park, YH ;
Lee, JS ;
Kim, WK ;
Kang, YK .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 35 (05) :251-255
[10]   An open, multi-centre, phase II clinical trial to evaluate the efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer [J].
Chao, Y. ;
Li, C. ;
Chao, T. Y. ;
Su, W. C. ;
Hsieh, R. K. ;
Wu, M. F. ;
Yeh, K. H. ;
Kao, W. Y. ;
Chen, L. T. ;
Cheng, A. L. .
BRITISH JOURNAL OF CANCER, 2006, 95 (02) :159-163
123456789